ATE157007T1 - 6-cyclohexyl-2'-0-methyl-adenosine hydrat und verwendungengen davon - Google Patents

6-cyclohexyl-2'-0-methyl-adenosine hydrat und verwendungengen davon

Info

Publication number
ATE157007T1
ATE157007T1 AT91810942T AT91810942T ATE157007T1 AT E157007 T1 ATE157007 T1 AT E157007T1 AT 91810942 T AT91810942 T AT 91810942T AT 91810942 T AT91810942 T AT 91810942T AT E157007 T1 ATE157007 T1 AT E157007T1
Authority
AT
Austria
Prior art keywords
formula
type
adenosine
disorders associated
cyclohexyl
Prior art date
Application number
AT91810942T
Other languages
English (en)
Inventor
Fulvio Gadient
Maria Milavec
Else Mueller
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4039060A external-priority patent/DE4039060A1/de
Priority claimed from GB919116212A external-priority patent/GB9116212D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Application granted granted Critical
Publication of ATE157007T1 publication Critical patent/ATE157007T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT91810942T 1990-12-07 1991-12-05 6-cyclohexyl-2'-0-methyl-adenosine hydrat und verwendungengen davon ATE157007T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4039060A DE4039060A1 (de) 1990-12-07 1990-12-07 Neue kristallform
GB919116212A GB9116212D0 (en) 1991-07-26 1991-07-26 New use of organic compounds

Publications (1)

Publication Number Publication Date
ATE157007T1 true ATE157007T1 (de) 1997-09-15

Family

ID=25899101

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91810942T ATE157007T1 (de) 1990-12-07 1991-12-05 6-cyclohexyl-2'-0-methyl-adenosine hydrat und verwendungengen davon

Country Status (9)

Country Link
EP (2) EP0774259A1 (de)
JP (2) JPH04290895A (de)
AT (1) ATE157007T1 (de)
AU (1) AU647216B2 (de)
CA (1) CA2056967A1 (de)
DE (1) DE69127350D1 (de)
HU (1) HUT61567A (de)
IE (1) IE914248A1 (de)
PT (1) PT99690B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
DE69232121T2 (de) * 1991-08-09 2002-06-20 Massachusetts Institute Of Technology, Cambridge Verwendungen einer proteinkinase von ton und neurofilament pk40
DK62692D0 (de) * 1992-05-14 1992-05-14 Novo Nordisk As
DK62592D0 (de) * 1992-05-14 1992-05-14 Novo Nordisk As
US5705491A (en) * 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
DK155292D0 (da) * 1992-12-23 1992-12-23 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
PL316985A1 (en) * 1994-05-10 1997-03-03 Sandoz Ltd Derivatives of adenosine
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
AU2022497A (en) * 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
AU4377397A (en) * 1996-10-14 1998-05-11 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
WO1999006059A2 (en) * 1997-07-30 1999-02-11 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
US6252061B1 (en) 1998-03-23 2001-06-26 Reliable Biopharmaceutical, Inc. Process for the production of 2-halo-6-aminopurine derivatives
JP3619017B2 (ja) 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
JP4534092B2 (ja) 2000-09-08 2010-09-01 第一三共株式会社 心不全治療剤
EP1258247A1 (de) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosin-Analoga für die Behandlung Von Insulinresistenz und Diabetes
EP1974732A4 (de) * 2005-11-24 2010-08-11 Univ Hokkaido Nat Univ Corp Therapeutisches mittel gegen neurodegenerative erkrankungen
CN101479268B (zh) * 2006-06-27 2012-08-08 Cbt发展有限公司 2-0’-甲基腺苷衍生物及其用作制备腺苷受体的激动剂或拮抗剂的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2230160A1 (de) * 1972-06-21 1974-01-31 Merck Patent Gmbh Adenosinderivat
AU579412B2 (en) * 1984-10-26 1988-11-24 Warner-Lambert Company N` - substituted adenosines
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
US4843066A (en) * 1986-11-27 1989-06-27 Nippon Zoki Pharmaceutical Co., Ltd. Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
US4962194A (en) * 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
GB2226027B (en) 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物

Also Published As

Publication number Publication date
PT99690A (pt) 1992-10-30
EP0490818B1 (de) 1997-08-20
DE69127350D1 (de) 1997-09-25
JPH09110700A (ja) 1997-04-28
EP0490818A1 (de) 1992-06-17
AU647216B2 (en) 1994-03-17
IE914248A1 (en) 1992-06-17
JPH04290895A (ja) 1992-10-15
HUT61567A (en) 1993-01-28
EP0774259A1 (de) 1997-05-21
CA2056967A1 (en) 1992-06-08
HU913662D0 (en) 1992-02-28
AU8888791A (en) 1992-06-11
PT99690B (pt) 1999-05-31

Similar Documents

Publication Publication Date Title
AU647216B2 (en) Improvements in or relating to organic compounds
ZA885242B (en) Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
BR9205640A (pt) Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares
DE69034043D1 (de) Pcp-rezeptor-liganden und deren verwendung
ITMI911299A1 (it) Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
ATE149833T1 (de) Verwendung von amino-2-trifluormethoxy-6- benzothiazol (riluzol) zur herstellung eines medikamentes zur behandlung von erkrankungen des motoneurons
FI933946A7 (fi) Hypoglykeemisinä aineina ja Alzheimerin taudin hoidossa käyttökelpoisia yhdisteitä
ATE76747T1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
DE69019111D1 (de) Ascorbinsäure-Tocopheryl-Phosphatdiester zur Hemmung der Maillard-Reaktion.
DE69719931D1 (de) Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren
PT920865E (pt) Utilizacao de ""norastemizole"" para o tratamento de disturbios alergicos
ATE274349T1 (de) Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
DE69420679D1 (de) Verwendung der 1-4-4-Aryl(oder Heteroaryl)-1-Piperazinylbutyl-1H-Azol-Derivate zur Herstellung von Arzneimitteln zur Behandlung der Störungen der Magensekretion
FR2635527B1 (fr) Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
DE69008466D1 (de) Verwendung des 6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-Dimethyluracils zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Harnwegsverstopfungen.
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
MX12192A (es) Composicion farmaceutica para reducir o impedir las arritmias
ES2085665T3 (es) Agente neuroprotector.
SE8802323L (sv) 8alfa-acylaminoergolin, dess framstaellning samt farmaceutiska kompositioner innehaallande detsamma
DE69206184D1 (de) Verwendung von Ibopamin zur Herstellung eines Arzneimittels zur Behandlung der optischen Neuropathie bei Glaukom.
ATE111732T1 (de) Verwendung von 1,4-dihydropyridinen zur herstellung eines arzneimittels, zur behandlung von neuropathien, die durch diabetes mellitus verursacht sind.
PT95825A (pt) Processo para a preparacao de composicoes farmaceuticas para a administracao transdermica contendo 2-amino-6-n-propilamino-4,5,6,7-tetra-hidrobenzotriazol
RU92015326A (ru) Средство для лечения конъюнктивита

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties